Investor updates Keyword Search Clear 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 Published on: 23 December 2011 Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer more Published on: 16 December 2011 Roche's personalized medicine Zelboraf receives positive opinion from European authority for the treatment of people with BRAF mutation-positive metastatic melanoma more Published on: 12 December 2011 First head to head study shows higher response rates for GA101 vs. MabThera/Rituxan without appreciable differences in safety in common type of blood cancer more Published on: 8 December 2011 Reminder: Roche conference call for investors and analysts from SABCS 2011 more Published on: 8 December 2011 Roche announces positive results of pivotal Phase III study with pertuzumab in HER2-positive metastatic breast cancer more Published on: 1 December 2011 Roche's cobas EGFR Mutation Test For Personalized Treatment Of Non-Small Cell Lung Cancer Receives CE Mark more Published on: 30 November 2011 Roche conference call for investors and analysts from SABCS 2011 more Published on: 30 November 2011 Roche to present important new data for HER2-positive breast cancer at 2011 San Antonio Breast Cancer Symposium more Published on: 23 November 2011 Roche purchases shares in tender offer for Anadys Pharmaceuticals more Published on: 18 November 2011 FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer more Published on: 9 November 2011 FDA accepts Roche's New Drug Application for vismodegib in advanced form of skin cancer more Published on: 31 October 2011 Reminder: Invitation to Late-stage pipeline event more Published on: 20 October 2011 Phase II study showed ocrelizumab maintained significant reduction in disease activity for multiple sclerosis patients for almost two years more Published on: 18 October 2011 Roche reports positive study of Herceptin given by subcutaneous injection more Published on: 17 October 2011 Roche signs definitive agreement to acquire Anadys Pharmaceuticals more Published on: 13 October 2011 Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches more Published on: 11 October 2011 Invitation to Late-stage pipeline event Monday, 7 November 2011 more Published on: 6 October 2011 Reminder: Invitation to Roche's Third Quarter Sales 2011 Conference Call more Published on: 30 September 2011 Roche wins first major public tender in Europe to screen women for cervical cancer with its Human Papillomavirus test more Published on: 29 September 2011 Roche receives clearance from the U.S. Food and Drug Administration for new generation of Accu-Chek Aviva Plus Test Strips for people with diabetes more Published on: 26 September 2011 Peginterferon alfa-2a “Pegasys®” Approved for Additional Indication of “Chronic Active Hepatitis B” more Published on: 26 September 2011 Anti-Cancer Agent, Avastin® Obtained Approval for Additional Indication and Dosage and Administration of “Inoperable or Recurrent Breast Cancer“ more Published on: 25 September 2011 Roche's investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancer more Published on: 24 September 2011 Avastin and pemetrexed combination gives lung cancer patients significantly more time without their disease progressing more Published on: 23 September 2011 Roche's Avastin receives positive opinion from European authority for the treatment of women with newly diagnosed advanced ovarian cancer more Published on: 19 September 2011 Roche highlights data that demonstrate a range of new approaches to target breast, skin and lung cancers at 2011 European Multidisciplinary Cancer Congress more Published on: 14 September 2011 Invitation to Roche's Third Quarter Sales 2011 Conference Call more Published on: 13 September 2011 Reminder Investor Day: Roche Diagnostics Enabling Personalised Healthcare more Published on: 8 September 2011 Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year more Published on: 2 September 2011 Chugai Initiates Clinical Trials for Multiple In-Licensed Compounds more Published on: 1 September 2011 Roche's Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer more Published on: 29 August 2011 Dalcetrapib phase II studies support the safety profile and potential for slowing of plaque progression in patients at risk of coronary heart disease more Published on: 25 August 2011 Roche Investor Science Call from ESC 2011: Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE more Published on: 22 August 2011 Investor Day: Roche Diagnostics Enabling Personalised Healthcare more Published on: 17 August 2011 FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of skin cancer more Published on: 15 August 2011 Roche Investor Science Event from ESC 2011: Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE more Published on: 15 August 2011 Chugai to In-license BRAF Inhibitor Vemurafenib more Published on: 4 August 2011 Roche's investigational treatment for asthma met its primary endpoint in a phase II study more Published on: 3 August 2011 Roche's RoACTEMRA approved in Europe for children living with a rare and severe form of arthritis more Published on: 22 July 2011 Roche's Tarceva gains positive CHMP opinion for first-line use in genetically distinct type of lung cancer more Published on: 22 July 2011 Full reconciliation of Chugai interim results into IFRS more Published on: 21 July 2011 Roche on track – full year earnings outlook increased more Published on: 19 July 2011 Anti-Human IL-6 Receptor Monoclonal Antibody "Actemra" Subcutaneous Injection Demonstrates Efficacy in Rheumatoid Arthritis in Phase III Clinical Study more Published on: 19 July 2011 Roche acquires mtm laboratories AG, expanding offering in cervical cancer testing more Published on: 15 July 2011 Pertuzumab combined with Herceptin and chemotherapy significantly extended the time people with HER2-positive metastatic breast cancer lived without their disease getting worse more Published on: 14 July 2011 Reminder: Invitation to Roche's Half Year Results for 2011 more Published on: 14 July 2011 Roche researchers develop antibody that crosses the blood-brain barrier more efficiently more Published on: 1 July 2011 Chronic Hepatitis C Treatment, Pegasys®, and Antiviral Drug, Copegus®, Obtained Approval for Additional Indication of Compensated Liver Cirrhosis Related to Hepatitis C more Published on: 1 July 2011 Anti-Cancer Agent, Tarceva® Obtained Approval for Additional Indication of “Pancreatic Cancer Not Amenable to Curative Resection“ and Measures for Proper Use more Published on: 30 June 2011 Roche’s Avastin receives broader EU label for women with metastatic breast cancer more Published on: 30 June 2011 Roche provides update from FDA hearing on Avastin for metastatic breast cancer more Published on: 29 June 2011 Two pivotal phase III Lucentis studies showed patients with diabetic macular edema experienced significant improvements in vision and fewer developed more advanced retinopathy more Published on: 24 June 2011 Invitation to Roche's Half Year Results for 2011 more Published on: 20 June 2011 Pivotal study showed vismodegib helped shrink tumours or heal lesions in people with rare form of advanced skin cancer more Published on: 5 June 2011 Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations more Published on: 4 June 2011 Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer more Published on: 3 June 2011 Tarceva nearly doubled the time people with a genetically distinct type of lung cancer lived without their disease getting worse more Published on: 2 June 2011 Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer more Published on: 27 May 2011 Roche Analyst Event at ASCO 2011 more Published on: 26 May 2011 RoACTEMRA could change the current standard of treatment for people living with rheumatoid arthritis more Published on: 20 May 2011 RoActemra offers a new option for children living with a rare and severe form of arthritis more Published on: 20 May 2011 Roche ASCO Planner more Published on: 19 May 2011 MetMAb in combination with Tarceva doubled the time people with lung cancer lived without their disease getting worse more Published on: 18 May 2011 Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO more Published on: 17 May 2011 Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C more Published on: 11 May 2011 New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer more Published on: 5 May 2011 Roche Analyst Event at ASCO 2011 more Published on: 26 April 2011 Long-Acting Erythropoiesis Stimulating Agent, “Mircera® Injection Syringe,” approved in Japan more Published on: 20 April 2011 FDA approves Rituxan/MabThera plus a steroid for use in severe forms of vasculitis more Published on: 20 April 2011 FDA Approves Roche's HPV Test for Identifying Women at Highest Risk for Cervical Cancer more Published on: 19 April 2011 Diversity of approaches in research continues to empower scientific excellence at Roche more Published on: 18 April 2011 FDA approves Actemra for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) more Published on: 15 April 2011 Roche gains positive CHMP opinion for the combination of Avastin with Xeloda as a first-line treatment for metastatic breast cancer in Europe more Published on: 14 April 2011 Roche Group’s first-quarter 2011 sales on track for full-year targets – positive results in seven key clinical trials more Published on: 7 April 2011 Reminder: Invitation to Roche's First Quarter Sales 2011 Conference Call - Thursday April 14th, 2011 more Published on: 7 April 2011 Roche announces positive Phase II results for trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer more Published on: 1 April 2011 Dalcetrapib Phase II studies dal-VESSEL and dal-PLAQUE show encouraging results more Published on: 28 March 2011 Second Lucentis Phase III study meets primary endpoint for improved vision in patients with diabetic macular edema (DME) more Published on: 21 March 2011 Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor in advanced basal cell carcinoma more Published on: 15 March 2011 Invitation to Roche's First Quarter Sales 2011 Conference Call - Thursday April 14th, 2011 more Published on: 15 March 2011 Roche acquires PVT to strengthen laboratory automation in clinical diagnostics more Published on: 10 March 2011 Phase III study of Lucentis showed rapid vision improvements sustained for two years in patients with diabetic macular edema more Published on: 10 March 2011 Herceptin® approved in Japan for additional indication of advanced or recurrent gastric cancer overexpressing HER2, which is not amenable to curative resection more Published on: 2 March 2011 European Commission continues to support Avastin in combination with paclitaxel as an effective treatment option for women with metastatic breast cancer more Published on: 1 March 2011 Roche Annual General Meeting: dividend raised by 10% more Published on: 25 February 2011 Pivotal Study Validates Roche’s cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer more Published on: 23 February 2011 Xeloda approved in Japan for Additional Indication of Advanced or Recurrent Gastric Cancer, which is Not Amenable to Curative Resection more Published on: 16 February 2011 Roche initiates phase III study investigating infusion-free administration of MabThera for patients with non-Hodgkin's lymphoma more Published on: 14 February 2011 Lucentis Phase III study meets primary endpoint for improving vision in patients with diabetic macular edema (DME) more Published on: 8 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer more Published on: 2 February 2011 Full reconciliation of Chugai 2010 results into IFRS more Published on: 2 February 2011 Solid overall results more Published on: 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma more Published on: 28 January 2011 Early successful readout of Tarceva study in a distinct form of lung cancer more Published on: 19 January 2011 Reminder: Invitation to Roche's Full Year Results for 2010 more Published on: 19 January 2011 Roche personalized investigational medicine shows survival benefit in advanced skin cancer more Published on: 17 January 2011 Changes to the Roche Corporate Executive Committee more Published on: 5 January 2011 FDA grants supplemental approval for ACTEMRA more Published on: 4 January 2011 Roche's Full Year Results for 2010 more
Published on: 23 December 2011 Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer more
Published on: 16 December 2011 Roche's personalized medicine Zelboraf receives positive opinion from European authority for the treatment of people with BRAF mutation-positive metastatic melanoma more
Published on: 12 December 2011 First head to head study shows higher response rates for GA101 vs. MabThera/Rituxan without appreciable differences in safety in common type of blood cancer more
Published on: 8 December 2011 Reminder: Roche conference call for investors and analysts from SABCS 2011 more
Published on: 8 December 2011 Roche announces positive results of pivotal Phase III study with pertuzumab in HER2-positive metastatic breast cancer more
Published on: 1 December 2011 Roche's cobas EGFR Mutation Test For Personalized Treatment Of Non-Small Cell Lung Cancer Receives CE Mark more
Published on: 30 November 2011 Roche to present important new data for HER2-positive breast cancer at 2011 San Antonio Breast Cancer Symposium more
Published on: 23 November 2011 Roche purchases shares in tender offer for Anadys Pharmaceuticals more
Published on: 18 November 2011 FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer more
Published on: 9 November 2011 FDA accepts Roche's New Drug Application for vismodegib in advanced form of skin cancer more
Published on: 20 October 2011 Phase II study showed ocrelizumab maintained significant reduction in disease activity for multiple sclerosis patients for almost two years more
Published on: 18 October 2011 Roche reports positive study of Herceptin given by subcutaneous injection more
Published on: 17 October 2011 Roche signs definitive agreement to acquire Anadys Pharmaceuticals more
Published on: 13 October 2011 Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches more
Published on: 6 October 2011 Reminder: Invitation to Roche's Third Quarter Sales 2011 Conference Call more
Published on: 30 September 2011 Roche wins first major public tender in Europe to screen women for cervical cancer with its Human Papillomavirus test more
Published on: 29 September 2011 Roche receives clearance from the U.S. Food and Drug Administration for new generation of Accu-Chek Aviva Plus Test Strips for people with diabetes more
Published on: 26 September 2011 Peginterferon alfa-2a “Pegasys®” Approved for Additional Indication of “Chronic Active Hepatitis B” more
Published on: 26 September 2011 Anti-Cancer Agent, Avastin® Obtained Approval for Additional Indication and Dosage and Administration of “Inoperable or Recurrent Breast Cancer“ more
Published on: 25 September 2011 Roche's investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancer more
Published on: 24 September 2011 Avastin and pemetrexed combination gives lung cancer patients significantly more time without their disease progressing more
Published on: 23 September 2011 Roche's Avastin receives positive opinion from European authority for the treatment of women with newly diagnosed advanced ovarian cancer more
Published on: 19 September 2011 Roche highlights data that demonstrate a range of new approaches to target breast, skin and lung cancers at 2011 European Multidisciplinary Cancer Congress more
Published on: 13 September 2011 Reminder Investor Day: Roche Diagnostics Enabling Personalised Healthcare more
Published on: 8 September 2011 Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year more
Published on: 2 September 2011 Chugai Initiates Clinical Trials for Multiple In-Licensed Compounds more
Published on: 1 September 2011 Roche's Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer more
Published on: 29 August 2011 Dalcetrapib phase II studies support the safety profile and potential for slowing of plaque progression in patients at risk of coronary heart disease more
Published on: 25 August 2011 Roche Investor Science Call from ESC 2011: Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE more
Published on: 17 August 2011 FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of skin cancer more
Published on: 15 August 2011 Roche Investor Science Event from ESC 2011: Phase II data from the endothelial function study dal-VESSEL and the imaging study dal-PLAQUE more
Published on: 4 August 2011 Roche's investigational treatment for asthma met its primary endpoint in a phase II study more
Published on: 3 August 2011 Roche's RoACTEMRA approved in Europe for children living with a rare and severe form of arthritis more
Published on: 22 July 2011 Roche's Tarceva gains positive CHMP opinion for first-line use in genetically distinct type of lung cancer more
Published on: 19 July 2011 Anti-Human IL-6 Receptor Monoclonal Antibody "Actemra" Subcutaneous Injection Demonstrates Efficacy in Rheumatoid Arthritis in Phase III Clinical Study more
Published on: 19 July 2011 Roche acquires mtm laboratories AG, expanding offering in cervical cancer testing more
Published on: 15 July 2011 Pertuzumab combined with Herceptin and chemotherapy significantly extended the time people with HER2-positive metastatic breast cancer lived without their disease getting worse more
Published on: 14 July 2011 Roche researchers develop antibody that crosses the blood-brain barrier more efficiently more
Published on: 1 July 2011 Chronic Hepatitis C Treatment, Pegasys®, and Antiviral Drug, Copegus®, Obtained Approval for Additional Indication of Compensated Liver Cirrhosis Related to Hepatitis C more
Published on: 1 July 2011 Anti-Cancer Agent, Tarceva® Obtained Approval for Additional Indication of “Pancreatic Cancer Not Amenable to Curative Resection“ and Measures for Proper Use more
Published on: 30 June 2011 Roche’s Avastin receives broader EU label for women with metastatic breast cancer more
Published on: 30 June 2011 Roche provides update from FDA hearing on Avastin for metastatic breast cancer more
Published on: 29 June 2011 Two pivotal phase III Lucentis studies showed patients with diabetic macular edema experienced significant improvements in vision and fewer developed more advanced retinopathy more
Published on: 20 June 2011 Pivotal study showed vismodegib helped shrink tumours or heal lesions in people with rare form of advanced skin cancer more
Published on: 5 June 2011 Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations more
Published on: 4 June 2011 Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer more
Published on: 3 June 2011 Tarceva nearly doubled the time people with a genetically distinct type of lung cancer lived without their disease getting worse more
Published on: 2 June 2011 Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer more
Published on: 26 May 2011 RoACTEMRA could change the current standard of treatment for people living with rheumatoid arthritis more
Published on: 20 May 2011 RoActemra offers a new option for children living with a rare and severe form of arthritis more
Published on: 19 May 2011 MetMAb in combination with Tarceva doubled the time people with lung cancer lived without their disease getting worse more
Published on: 18 May 2011 Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO more
Published on: 17 May 2011 Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C more
Published on: 11 May 2011 New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer more
Published on: 26 April 2011 Long-Acting Erythropoiesis Stimulating Agent, “Mircera® Injection Syringe,” approved in Japan more
Published on: 20 April 2011 FDA approves Rituxan/MabThera plus a steroid for use in severe forms of vasculitis more
Published on: 20 April 2011 FDA Approves Roche's HPV Test for Identifying Women at Highest Risk for Cervical Cancer more
Published on: 19 April 2011 Diversity of approaches in research continues to empower scientific excellence at Roche more
Published on: 18 April 2011 FDA approves Actemra for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) more
Published on: 15 April 2011 Roche gains positive CHMP opinion for the combination of Avastin with Xeloda as a first-line treatment for metastatic breast cancer in Europe more
Published on: 14 April 2011 Roche Group’s first-quarter 2011 sales on track for full-year targets – positive results in seven key clinical trials more
Published on: 7 April 2011 Reminder: Invitation to Roche's First Quarter Sales 2011 Conference Call - Thursday April 14th, 2011 more
Published on: 7 April 2011 Roche announces positive Phase II results for trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer more
Published on: 1 April 2011 Dalcetrapib Phase II studies dal-VESSEL and dal-PLAQUE show encouraging results more
Published on: 28 March 2011 Second Lucentis Phase III study meets primary endpoint for improved vision in patients with diabetic macular edema (DME) more
Published on: 21 March 2011 Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor in advanced basal cell carcinoma more
Published on: 15 March 2011 Invitation to Roche's First Quarter Sales 2011 Conference Call - Thursday April 14th, 2011 more
Published on: 15 March 2011 Roche acquires PVT to strengthen laboratory automation in clinical diagnostics more
Published on: 10 March 2011 Phase III study of Lucentis showed rapid vision improvements sustained for two years in patients with diabetic macular edema more
Published on: 10 March 2011 Herceptin® approved in Japan for additional indication of advanced or recurrent gastric cancer overexpressing HER2, which is not amenable to curative resection more
Published on: 2 March 2011 European Commission continues to support Avastin in combination with paclitaxel as an effective treatment option for women with metastatic breast cancer more
Published on: 25 February 2011 Pivotal Study Validates Roche’s cobas® HPV Test with HPV-16 and 18 Genotyping for Identifying Women at Highest Risk for Cervical Cancer more
Published on: 23 February 2011 Xeloda approved in Japan for Additional Indication of Advanced or Recurrent Gastric Cancer, which is Not Amenable to Curative Resection more
Published on: 16 February 2011 Roche initiates phase III study investigating infusion-free administration of MabThera for patients with non-Hodgkin's lymphoma more
Published on: 14 February 2011 Lucentis Phase III study meets primary endpoint for improving vision in patients with diabetic macular edema (DME) more
Published on: 8 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer more
Published on: 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma more
Published on: 28 January 2011 Early successful readout of Tarceva study in a distinct form of lung cancer more
Published on: 19 January 2011 Roche personalized investigational medicine shows survival benefit in advanced skin cancer more